Year All202320222021202020192018 Nov 15, 2023 Mural Oncology Launches to Advance Pipeline of Novel Engineered Cytokine Immunotherapies Oct 31, 2023 Alkermes Announces Effectiveness of Mural Oncology Form 10 Registration Statement Oct 10, 2023 Mural Oncology to Host Investor Webcast on October 17 Jun 01, 2023 Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc Jan 17, 2023 Alkermes Awarded Innovation Passport Designation by the MHRA (UK) for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
Nov 15, 2023 Mural Oncology Launches to Advance Pipeline of Novel Engineered Cytokine Immunotherapies
Jun 01, 2023 Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc
Jan 17, 2023 Alkermes Awarded Innovation Passport Designation by the MHRA (UK) for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
